Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage Pharmaceuticals ... to an Investigational New Drug (IND) application for the ... recently completed a study in a rat model of ... significant efficacy and a more rapid onset of action ...
(Date:8/31/2015)... 31, 2015 LabStyle Innovations Corp. (OTCQB: ... today announced it recently closed a round of ... used to support the global rollout and initial ... cloud-based, diabetes management solution that includes novel software ... glucose monitoring device, and for working capital purposes. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Proove Biosciences, Inc. ... Technology Alliance Annual High Tech Awards. , Now in its 22nd year, this ... which drive innovation here, across the nation and around the world. The OC Tech ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is ... will present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical ... Asia’s largest analytical and scientific instruments show which will be held at International ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... the Biomedical Development Center, plans for the incubator are not ... is seeking $15 million in backing. But because there is ... its founders are looking at alternative locations around the Bay ... the massive Catellus development. , ,The timing may be ...
... windows exhale a dying breath, HTML-based email messages find themselves ... plain text email messages are becoming more popular, and more ... Lucid Marketing survey indicated that 53% of ... ones. Although theyve conducted this survey before, this is ...
... business executives from excellent ones is the ability to ... unusual competence in discernment or perception, or intelligent foresight. ... proven most people dont have that ability. During the ... They talked an interesting game, but when the real ...
Cached Biology Technology:S.F. biotech incubator ready to hatch 2S.F. biotech incubator ready to hatch 3Style Without Substance: Will HTML Email Survive Abuse? 2Leadership is all about Vision 2Leadership is all about Vision 3
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... researchers have found that years after experiencing childhood ... than expected in their elderly counterparts, but rather ... commensurate with normal aging. , "Other researchers have ... later in life, but we've actually found it ...
... of a nation-wide study published in the latest issue ... Physicians in AIDS Care (JIAPAC), HIV positive patients and ... and how it's treated. , The study uncovered differences ... of treatment, the various goals of treatment, and even ...
... of poultry flocks could make the spread of deadly ... at the Universities of Edinburgh and Warwick have found. ... are effective on individual birds, the disease is likely ... been protected. The study, published in Nature journal, is ...
Cached Biology News:Survivors of childhood polio do well decades later as they age 2Bird flu study highlights need to vaccinate flocks effectively 2